Low or High Dose of Dexamethasone in Patients With Respiratory Failure by COVID-19 : Efficacy of Low or High Dose of Dexamethasone in Patients With Respiratory Failure by COVID-19

Objective: The investigators aim to assess the efficacy of high dose of dexamethasone (20 mg / day 5 days, and 10 mg/day 5 days) versus low dose of dexamethasone (6 mg/day 10 days) in patients with respiratory failure by COVID-19..

Medienart:

Klinische Studie

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

ClinicalTrials.gov - (2021) vom: 20. Okt. Zur Gesamtaufnahme - year:2021

Sprache:

Englisch

Links:

Volltext [kostenfrei]

Themen:

610
COVID-19
Medical Condition: Covid19, Corticosteroids
Phase: Phase 4
Recruitment Status: Completed
Respiratory Insufficiency
Study Type: Interventional

Anmerkungen:

Source: Link to the current ClinicalTrials.gov record., First posted: January 27, 2021, Last downloaded: ClinicalTrials.gov processed this data on November 01, 2021, Last updated: November 03, 2021

Study ID:

NCT04726098
HIGHLOWDEXA-COVID
2020-005702-25

Veröffentlichungen zur Studie:

fisyears:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

CTG003651274